Core Viewpoint - Collegium Pharmaceutical, Inc. is set to report its second quarter 2025 financial results on August 7, 2025, before market opening, followed by a live conference call at 8:00 a.m. ET [1]. Company Overview - Collegium Pharmaceutical is focused on becoming a leading, diversified biopharmaceutical company dedicated to improving the lives of individuals with serious medical conditions [3]. - The company has a strong portfolio in responsible pain management medications and has recently acquired Jornay PM, a treatment for ADHD, marking its entry into neuropsychiatry [3]. - Collegium's growth strategy emphasizes expanding its commercial portfolio, with Jornay PM identified as the primary growth driver, while maintaining disciplined capital deployment [3].

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2 ...